Security key
15117B202
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX)
CUSIP: 15117B202
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 80,000,000
- Total 13F shares
- 72,686,329
- Share change
- -1,047,957
- Total reported value
- $1,479,214,886
- Put/Call ratio
- 243%
- Price per share
- $20.35
- Number of holders
- 178
- Value change
- -$18,971,957
- Number of buys
- 111
- Number of sells
- 69
Report period
Q2 2025
Institutions
178
Top holders
10
CLDX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Celldex Therapeutics, Inc. SEC filings
Celldex Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 15117B202
Recent filing periods:
Ownership snapshot
Top shareholders of CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
BlackRock, Inc.
13D/G signal
BlackRock, Inc.
Evidence rows
50
Latest as of
31 Mar 2025
13D/G
13F
Lead comparable stake: 7.3%
13D/G row: BlackRock, Inc.
Showing first 8 of 50 holder rows.
Open remaining rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
13F
Company
|
7.3%
|
$100,867,802
4,819,293 shares
|
-$13,842,621 | 31 Mar 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
13D/G
Company
|
2%
from 13D/G
|
$68,181,159
3,754,793 shares
|
— | 31 Mar 2025 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
10%
|
$151,627,841
8,354,151 shares
|
— | 31 Mar 2025 |
| Kynam Capital Management, LP |
13F
Company
|
8.1%
|
$117,975,000
6,500,000 shares
|
— | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
6.7%
|
$97,648,661
5,380,091 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
4.9%
|
$70,756,595
3,898,435 shares
|
— | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
4.3%
|
$61,901,000
3,410,499 shares
|
— | 31 Mar 2025 |
| Commodore Capital LP |
13F
Company
|
4%
|
$58,080,000
3,200,000 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
178
Shares
72,686,329
Rows loaded
178
| Investor | Option | Weight % | Change % | Reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. An asterisk next to the price means the price is likely invalid.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
170
Q2 2025 holders
178
Holder diff
8
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend